Spun out from Kleiner Perkins, the founding partners sought to build a global firm, investing in innovation in every geography, while bringing its unique perspectives in life sciences experience to benefit global company building.
To date, Panacea Venture raised three USD funds from renowned institutional funds as well as strategic investors and has investments in more than 30 private companies and several public companies.
Panacea incubates early-stage companies with breakthrough technologies and discoveries that can potentially address unmet medical needs to enhance quality of life on a global scale.
We build and capture value from company formation to expansion stage to public market investing.
Myrtelle announces significant reductions in N-Acetylaspartate (NAA), a key biomarker for Canavan Disease.
Myrtelle announces significant reductions in N-Acetylaspartate (NAA), a key biomarker for Canavan Disease.